Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
OFF episode quality of life impact scale (OFFELIA): A new measure of quality of life for off episodes in Parkinson's disease.
Kuharic M, Kulbokas V, Hanson K, Nazari JL, Shah KK, Nguyen A, Hensle T, Marras C, Armstrong MJ, Jalundhwala YJ, Pickard AS. Kuharic M, et al. Among authors: jalundhwala yj. Parkinsonism Relat Disord. 2024 Mar 12;123:106070. doi: 10.1016/j.parkreldis.2024.106070. Online ahead of print. Parkinsonism Relat Disord. 2024. PMID: 38503261 Free article.
The Cost Effectiveness of Levodopa-Carbidopa Intestinal Gel in the Treatment of Advanced Parkinson's Disease in England.
Chaudhuri KR, Pickard AS, Alobaidi A, Jalundhwala YJ, Kandukuri PL, Bao Y, Sus J, Jones G, Ridley C, Oddsdottir J, Najle-Rahim S, Madin-Warburton M, Xu W, Schrag A. Chaudhuri KR, et al. Among authors: jalundhwala yj. Pharmacoeconomics. 2022 May;40(5):559-574. doi: 10.1007/s40273-022-01132-y. Epub 2022 Mar 21. Pharmacoeconomics. 2022. PMID: 35307793 Free PMC article.
Patterns of Daily Motor-Symptom Control with Carbidopa/Levodopa Enteral Suspension Versus Oral Carbidopa/Levodopa Therapy in Advanced Parkinson's Disease: Clinical Trial Post Hoc Analyses.
Pahwa R, Aldred J, Gupta N, Terasawa E, Garcia-Horton V, Steffen DR, Kandukuri PL, Chaudhari VS, Jalundhwala YJ, Bao Y, Kukreja P, Isaacson SH. Pahwa R, et al. Among authors: jalundhwala yj. Neurol Ther. 2022 Jun;11(2):711-723. doi: 10.1007/s40120-022-00332-0. Epub 2022 Feb 22. Neurol Ther. 2022. PMID: 35192177 Free PMC article.
Does the 5-2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5-2-1-positive patients in 7 countries.
Malaty IA, Martinez-Martin P, Chaudhuri KR, Odin P, Skorvanek M, Jimenez-Shahed J, Soileau MJ, Lindvall S, Domingos J, Jones S, Alobaidi A, Jalundhwala YJ, Kandukuri PL, Onuk K, Bergmann L, Femia S, Lee MY, Wright J, Antonini A. Malaty IA, et al. Among authors: jalundhwala yj. BMC Neurol. 2022 Jan 24;22(1):35. doi: 10.1186/s12883-022-02560-1. BMC Neurol. 2022. PMID: 35073872 Free PMC article.
Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinson's Disease: Real-World Evidence From G7 Countries.
Antonini A, Pahwa R, Odin P, Henriksen T, Soileau MJ, Rodriguez-Cruz R, Isaacson SH, Merola A, Lindvall S, Domingos J, Alobaidi A, Jalundhwala YJ, Kandukuri PL, Parra JC, Kukreja PK, Onuk K, Bergmann L, Pike J, Ray Chaudhuri K. Antonini A, et al. Among authors: jalundhwala yj. Neurol Ther. 2022 Mar;11(1):303-318. doi: 10.1007/s40120-021-00313-9. Epub 2022 Jan 11. Neurol Ther. 2022. PMID: 35015215 Free PMC article.
Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications.
Antonini A, Odin P, Schmidt P, Cubillos F, Standaert DG, Henriksen T, Jimenez-Shahed J, Alobaidi A, Jalundhwala YJ, Bao Y, Zamudio J, Parra JC, Kukreja P, Onuk K, Skalicky AM, Kleinman L, Jones E, Metz S, Fernandez HH. Antonini A, et al. Among authors: jalundhwala yj. Parkinsonism Relat Disord. 2021 Nov;92:59-66. doi: 10.1016/j.parkreldis.2021.10.009. Epub 2021 Oct 13. Parkinsonism Relat Disord. 2021. PMID: 34695657 Free article.
23 results